Alps Group Inc. (ALPS), a biotechnology research and healthcare platform, announced that on May 15, 2026, the firm received a letter from the Listing Qualifications Department of the Nasdaq stating that the firm was not in compliance with the continued listing requirement to maintain a minimum bid price of $1 per share for 30 consecutive business days.
Nasdaq has provided a compliance period of 180 calendar days, or until November 11, 2026, for the firm to regain compliance. The firm is currently evaluating options to regain compliance and intends to regain compliance.
APLS has traded between $0.56 and $2.90 over the last year. The stock closed Tuesday's trade at $0.77, down 8.99%.
For more such news For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.